However, recent studies have shown that GIPR-GLP1R co-agonists or GIPR-GLP1R unimolecular agonists are unexpectedly more effective anti-hyperglycemic and anti-obesity agents compared to GLP1R agonist control [16, 17]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.